Leukemia Clinical Trials in Ohio

Showing 921-940 of 1,600 trials

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

NCT01177540

The purpose of this study is to provide data on the activity of a standard daunorubicin, cytarabine, and etoposide (ADE) induction plus epigenetic priming with decitabine as assessed by standard measures of complete remission (CR), leukemia free survival (LFS) and overall survival (OS), as well as, on minimal residual disease (MRD). It will also provide necessary data on the safety and Pharmacokinetics (PK) of decitabine in pediatric patients that is currently unavailable.

Pediatric Acute Myelogenous Leukemia (AML)

Eisai Inc.25 participantsStarted Mar 2011

Phoenix, Arizona, United States • Madera, California, United States • Aurora, Colorado, United States +19 more locations

TERMINATEDPhase 1/232 miles

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535

This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine and daunorubicin in induction, in combination with cytarabine in consolidation, and as a single agent in maintenance for treating participants with acute myeloid leukemia (AML).

Acute Myeloid Leukemia

Hoffmann-La Roche24 participantsStarted Mar 2019

Los Angeles, California, United States • Denver, Colorado, United States • Chicago, Illinois, United States +23 more locations

PreviousPage 47 of 80Next

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Leukemia Trials in Other Cities

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

A Study of LY3023414 in Participants With Advanced Cancer

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

Other Conditions in Ohio